Northwest Biotherapeutics (NWBO) Free Cash Flow (2010 - 2026)

Northwest Biotherapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$12.6 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 32.88% year-over-year to -$12.6 million in Q1 2026; TTM through Mar 2026 was -$49.4 million, a 10.02% increase from a year earlier, with the FY2025 full-year figure at -$46.3 million, up 20.27% from the prior year.
• Free Cash Flow rose to -$12.6 million in Q1 2026 per NWBO's latest filing, from -$15.7 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$7.0 million in Q2 2025 and bottomed at -$20.3 million in Q4 2024.
• The 5-year median for Free Cash Flow is -$13.0 million (2022), against an average of -$13.5 million.
• Across the five-year window, Free Cash Flow slumped 83.75% in 2022 and jumped 58.18% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$11.0 million in 2022, then plunged by 57.83% to -$17.4 million in 2023, then declined by 16.59% to -$20.3 million in 2024, then gained by 22.66% to -$15.7 million in 2025, then grew by 19.34% to -$12.6 million in 2026.
• Per Business Quant, the three latest NWBO Free Cash Flow figures stand at -$12.6 million (Q1 2026), -$15.7 million (Q4 2025), and -$14.1 million (Q3 2025).